News

Consider Chemotherapy after Induction Failure for Childhood Leukemia

View on the News

Not a 'Single Entity with a Uniform Prognosis'

The study by Dr. Schrappe and colleagues, a "remarkable collaborative effort," demonstrates that "induction failure is not a single entity with a uniform prognosis but rather exhibits biologic and prognostic heterogeneity," said Dr. Karen R. Rabin.

Moreover, the "striking" finding that chemotherapy is superior to stem-cell transplantation in certain subgroups of patients "may substantially affect current practice, since stem-cell transplantation has generally been accepted as the preferred treatment for all cases of induction failure," she said.

Dr. Rabin is with the division of pediatric hematology/oncology at Texas Children’s Cancer Center and Baylor College of Medicine, Houston. She reported no financial conflicts of interest. These remarks were taken from her editorial comment accompanying Dr. Schrappe’s report (N. Engl. J. Med. 2012;366:1445-6).


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Numerous hospitals, charities, and government agencies supported this study. Dr. Schrappe reported ties to Medoc and EUSA Pharm; his associates reported ties to numerous industry sources.

Pages

Recommended Reading

FDA Steps Up Cancer Surveillance of TNF Blockers
MDedge Pediatrics
New Data Support Continuing Hydroxyurea for Pediatric Sickle Cell
MDedge Pediatrics
Return ED Visits by Sickle Cell Patients Common
MDedge Pediatrics
IGF-I Doesn't Predict Late Complications in Childhood Cancer Survivors
MDedge Pediatrics
New Scoring System Devised for Youth With Hodgkin's Lymphoma
MDedge Pediatrics
58-Plus Chromosomes Bode Well in Childhood B-ALL
MDedge Pediatrics
FDA Acts to Curb Doxorubicin, Methotrexate Shortages
MDedge Pediatrics
Her Chief Complaint Is ... And by the Way She’s Also Pregnant
MDedge Pediatrics
Infants Left Out of Survival Gains in Childhood Leukemia
MDedge Pediatrics
NCCN Cancer Guidelines Focus on Adolescent, Young Adult Needs
MDedge Pediatrics